T14 drives upstream Alzheimer’s neurodegeneration
PrimaryNeuro-Bio’s central causal theory is that T14, a 14-amino-acid bioactive peptide, is not merely associated with Alzheimer’s disease but acts as an upstream toxic driver of neurodegeneration. The claim is that T14 becomes elevated in Alzheimer’s brains and initiates neuronal toxicity before or upstream of amyloid pathology, making it a mechanistic target for early intervention rather than a downstream disease marker. Testable predictions are that T14 levels should rise before or during presymptomatic Alzheimer’s disease, correlate with neurodegenerative pathology, and reproduce disease-relevant toxicity in cellular or animal models. Conversely, blocking T14 activity should reduce toxic signaling and improve neurodegeneration-associated outcomes.
Popperian evaluation
The premise is biologically plausible, but still thin. T14 has a named molecular identity, a proposed receptor target, and a testable toxicity route through alpha7 nicotinic acetylcholine receptor binding, calcium influx, mTORC1 activation, impaired autophagy, and beta-amyloid accumulation. That is enough to treat the theory as a real mechanistic claim. The weak point is causal ordering: elevated T14 in Alzheimer’s or presymptomatic tissue does not by itself prove that T14 starts the disease process.
Supporting evidence: T14 is reported to be elevated in Alzheimer’s brains.; T14 is reported to be elevated in presymptomatic Alzheimer’s disease.; T14 is described as binding alpha7 nicotinic acetylcholine receptor and triggering calcium influx, mTORC1 activation, impaired autophagy, and beta-amyloid accumulation.; T14-induced toxicity is modeled in PC12 cells using calcium influx and cell viability assays.
Counter evidence: The evidence context still relies on the assumption that T14 elevation reflects causal disease biology rather than secondary damage, comorbidity, or measurement artifact.; PC12-cell calcium influx and viability assays are only proxy systems for Alzheimer’s-relevant neuronal toxicity.; The provided evidence does not show that T14 elevation consistently precedes amyloid pathology in longitudinal human cohorts.
The theory explains several linked observations in one chain: T14 rises, binds alpha7 nicotinic receptors, drives calcium influx, perturbs autophagy, and can be blocked by antibodies or antagonists. That is coherent. The problem is that coherence is not dominance over alternatives. Alzheimer’s has many plausible upstream drivers, including amyloid processing, tau pathology, vascular injury, immune activation, and metabolic stress. The current evidence shows that T14 can fit the disease biology. It does not yet show that T14 explains the observations better than those other routes.
Supporting evidence: The proposed cascade connects T14 elevation to neuronal toxicity and Alzheimer’s-relevant pathology.; Anti-T14 antibodies and receptor blockers reduce T14-induced toxic calcium influx in PC12 cells.; NBP6B antagonizes T14-induced toxicity with nanomolar potency and selectivity in PC12 assays.; NBP14 is reported to produce cognitive benefits in a preclinical mouse model.
Counter evidence: Blocking T14-induced toxicity in PC12 cells does not prove that endogenous T14 drives human Alzheimer’s progression.; The evidence context does not provide head-to-head explanatory tests against amyloid-first, tau-first, inflammatory, vascular, or mixed-cause models.; The reported preclinical cognitive benefit is supportive, but the model details and disease relevance are not described here.
This is the strongest Popperian feature. The theory makes clear bets that could fail: T14 should rise before or during presymptomatic Alzheimer’s disease, track neurodegenerative pathology, reproduce disease-relevant toxicity, and lose that toxicity when T14 is blocked. A clean negative result in longitudinal human samples, disease-relevant neuronal models, or intervention experiments would hurt the theory directly. That is good science architecture, even if the current evidence has not yet carried the whole load.
Supporting evidence: The theory predicts that T14 levels should rise before or during presymptomatic Alzheimer’s disease.; The theory predicts that T14 levels should correlate with neurodegenerative pathology in Alzheimer’s disease.; The theory predicts that exogenous or elevated T14 should reproduce disease-relevant toxicity in cellular or animal models.; The theory predicts that blocking T14 activity should reduce toxic signaling and improve neurodegeneration-associated outcomes.
Counter evidence: Some current tests use PC12-cell calcium influx and viability, which are easier to satisfy than human disease endpoints.; The evidence context does not define exact human thresholds, time windows, or effect sizes that would count as failure.; If future versions of the theory allow T14 to be both upstream and downstream depending on context, falsifiability would weaken.
Reasoning tree
Public endorsements
There is no direct public statement from Adam Khan in the provided evidence about T14, Alzheimer’s causality, or Neuro-Bio’s claim that T14 is an upstream driver of neurodegeneration. The only record is a patent excerpt about a separate neuroprotective peptide context, and it does not show Adam Khan endorsing, mentioning, or contradicting this specific theory.
Susan Greenfield publicly discusses Neuro-Bio's Alzheimer's work and describes NBP-14 as a compound intended to halt the root causes of neuronal degeneration. That is consistent with discussing the company's causal theory, but the provided evidence does not include a direct public statement from her explicitly backing the specific claim that T14 is an upstream driver of Alzheimer's neurodegeneration.
Evidence publication IDs: 58907071-633b-4d87-8e64-59deadd199c5
The public evidence here shows Professor Clive Coen on Neuro-Bio's Science Advisory Board, but it does not show him publicly endorsing or even discussing the claim that T14 is an upstream toxic driver of Alzheimer's neurodegeneration. The patent record is about Arf6 in Alzheimer's disease and lists Katrijn Coen, which appears to be a different person and a different mechanism.
Sara Garcia-Ratés is not just affiliated with Neuro-Bio, she is identified publicly as its CSO and employee. More importantly, the cited Alzheimer’s Association publication names her on work described as providing evidence for a novel neuronal mechanism driving Alzheimer’s disease upstream of amyloid, which matches the company’s T14 causal theory closely enough to count as a public endorsement rather than a passing mention.